Business
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
TORONTO, ON / ACCESSWIRE / August 21, 2024 / Theralase ® Technologies Inc. (" Theralase &#...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes DrugTORONTO, ON / ACCESSWIRE / August 21, 2024 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin® has been proven preclinically to be activated by Metformin, a common diabetes drug, without the use of light and/or radiation.Even more interesting is that because Rutherrin® and Metformin are both scientifically proven to cross the blood-brain barrier, as well as tumour-specific blood barriers, this new discovery potentially allows the precise targeting of cancer cells by Rutherrin® anywhere inside the body, including the brain, followed by their synergistic activation by Metformin.Metformin, an anti-diabetic agent, was approved by the U.S. Food and Drug Administration in 1994 for the treatment of Type 2 diabetes (a medical condition resulting from the insufficient production of insulin, causing high blood sugar). Metformin is currently the only anti-diabetic medication prescribed for the prophylactic (intended to prevent disease) treatment of prediabetes, as recommended by the American Diabetes Association.In order to determine if Metformin has the ability to activate Rutherrin® to produce Reactive Oxygen Species (\"ROS\"), for the destruction of treatment resistant, Non-Small Cell Lung Cancer (\"NSCLC\") cells, NSCLC cells were treated with either Rutherrin®, Metformin or a combination of both for 24 hours.As can be seen in Figure 1.0, Rutherrin® on its own increases ROS production, without any external stimuli, leading to cancer cell death; however, this ROS production is significantly increased by activating Rutherrin® with Metformin (p<0.001). Figure 1.0: Reactive Oxygen Species Production in NSCLC Cells Treated with Rutherrin®, Metformin or Their CombinationTo further explore the activation of Rutherrin® by Metformin, an additional set of experiments were conducted, where the cells were treated with either Rutherrin®, Metformin or both for 24 hours and then irradiated ...